Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Income Statement
- Common-Size Balance Sheet: Assets
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Selected Financial Data since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
The financial data exhibits several distinct trends over the analyzed periods, reflecting changes in profitability and efficiency metrics.
- Gross Profit Margin
- The gross profit margin remained relatively stable at a high level, fluctuating slightly around 88% from March 2021 through March 2024. Starting at approximately 88.14% in early 2021, it gradually declined from 87.21% in March 2024 to around 86.03% by the end of March 2025, indicating a slight erosion in gross profitability over time.
- Operating Profit Margin
- The operating profit margin exhibited notable volatility. It initially increased to above 47% by mid-2021, followed by fluctuations between approximately 33.93% and 48.85% up through late 2023. However, a sharp decline is observed starting in early 2024, where operating margin fell into negative territory, reaching -6.69% by the end of March 2025. This indicates deteriorating operational efficiency or increased costs impacting operations significantly in the latest periods.
- Net Profit Margin
- Net profit margin tracked a pattern similar to operating margin but with less volatility in the earlier periods. It peaked somewhat above 43% in early 2021, declined to around 29.8% to 38.26% between late 2020 and late 2022, and stabilized near the mid-30% range through 2023. However, starting in early 2024, a sharp downturn led to negative margins by March 2025, reaching -8.91%, suggesting that net income was adversely affected by the factors impacting operating profit as well as possibly rising non-operating expenses or charges.
- Return on Equity (ROE)
- The return on equity followed a downward trend after peaking in early 2021 near 31.22%. It declined progressively to around 20.59% by late 2023. A pronounced decline occurred beginning in 2024, with ROE turning negative and dropping to -5.99% by the first quarter of 2025, reflecting substantial erosion in shareholder returns likely linked to declining profitability and potential balance sheet impacts.
- Return on Assets (ROA)
- ROA showed a steady decline from roughly 23.07% in early 2021 to near 15.92% in late 2023. Similar to ROE, ROA sharply declined into negative territory during 2024 and into 2025, falling to -4.32%, indicating reduced asset efficiency and lower overall profitability generated from company assets over time.
Overall, the data reveals that although the company maintained strong gross margins throughout the early periods, profitability at the operating and net levels deteriorated notably starting in early 2024. This deterioration extended to the major return metrics of ROE and ROA, which turned negative by the end of the analyzed timeframe. The negative trend in these profitability and return measures suggests challenges in controlling costs or revenue declines that have a substantial impact on financial performance and shareholder value in the most recent quarters.
Return on Sales
Return on Investment
Gross Profit Margin
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Gross profit | ||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||
Gross profit margin1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Gross profit margin = 100
× (Gross profitQ1 2025
+ Gross profitQ4 2024
+ Gross profitQ3 2024
+ Gross profitQ2 2024)
÷ (RevenuesQ1 2025
+ RevenuesQ4 2024
+ RevenuesQ3 2024
+ RevenuesQ2 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Gross Profit
- The gross profit exhibited an overall upward trend from the first quarter of 2020 through early 2025. Starting at approximately $1.35 billion in March 2020, it increased steadily with occasional fluctuations, reaching a peak of about $2.49 billion in December 2024. Despite minor declines in some quarters, such as between Q3 and Q4 of 2022 and Q3 and Q4 of 2023, the general long-term direction remains positive.
- Revenues
- Revenues followed a consistent growth trajectory throughout the period analyzed, increasing from roughly $1.52 billion in March 2020 to nearly $2.91 billion by December 2024. The data indicate steady quarter-over-quarter increases with some periods of modest contraction or leveling off, notably seen in the final quarter of 2024 and early 2025, when revenues declined slightly from the previous quarter.
- Gross Profit Margin
- Gross profit margins were relatively stable across the reported quarters from March 2021 to March 2025. Margins hovered around the high 80% range, starting near 88.1% in early 2021 and gradually decreasing to about 86.0% by early 2025. This gradual compression suggests that while the company maintained strong profitability at the gross level, there was a slow and steady reduction in the efficiency or pricing power relative to revenues over time.
- Summary of Trends and Insights
- Over the observed period, the company demonstrated robust revenue and gross profit growth, reflecting expansion in business scale and volume. The relatively flat gross margin percentage indicates that increases in gross profit closely tracked revenue growth, though the slight downward trend in margin percentage may warrant further investigation to understand cost pressures or pricing changes. The high and stable gross margins indicate effective cost control or premium pricing, but the modest decrease suggests potential margin pressures, possibly from increased costs, competitive pricing, or shifts in product mix. The minor fluctuations in gross profit and revenues in some quarters also highlight the normal variability in operating conditions.
Operating Profit Margin
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Income (loss) from operations | ||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||
Operating profit margin1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Operating profit margin = 100
× (Income (loss) from operationsQ1 2025
+ Income (loss) from operationsQ4 2024
+ Income (loss) from operationsQ3 2024
+ Income (loss) from operationsQ2 2024)
÷ (RevenuesQ1 2025
+ RevenuesQ4 2024
+ RevenuesQ3 2024
+ RevenuesQ2 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data over the observed periods reveals several important trends in key operational metrics.
- Income (loss) from operations
- Income from operations generally exhibited strong performance with positive figures in most quarters, reaching a peak around September 2021. However, significant volatility is apparent, notably in June 2021 and June 2024, where substantial losses are recorded. Despite these fluctuations, the company maintained operational income mostly above $600 million, suggesting overall operational resilience with occasional disruptions.
- Revenues
- Revenues showed a consistent upward trend across the entire timeframe, increasing from approximately $1.5 billion in early 2020 to over $2.9 billion by the first quarter of 2025. This steady growth indicates effective sales expansion and strengthened market demand. The periodic increase each quarter reflects sustained business momentum without major declines.
- Operating profit margin
- The operating profit margin displayed considerable variation. Early measures indicate margins in the mid-30% to high-40% range for most of the periods up to 2023, suggesting high efficiency in operations relative to revenue. Nonetheless, there is a marked drop in the margin in the last observed years, with negative margins evident from March 2024 onward. These negative margins imply a significant erosion of profitability in recent quarters, potentially linked to the operating losses noted above.
In summary, the company demonstrated robust revenue growth and historically strong operating profitability. However, recent periods have revealed operational challenges marked by sizeable losses and negative operating margins, which merit further investigation to understand underlying causes and to develop corrective measures.
Net Profit Margin
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Net income (loss) | ||||||||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||
Net profit margin1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Net profit margin = 100
× (Net income (loss)Q1 2025
+ Net income (loss)Q4 2024
+ Net income (loss)Q3 2024
+ Net income (loss)Q2 2024)
÷ (RevenuesQ1 2025
+ RevenuesQ4 2024
+ RevenuesQ3 2024
+ RevenuesQ2 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Net Income (Loss)
- The net income demonstrates notable fluctuations across the analyzed periods. Initially, there is a substantial increase from approximately 603 million USD in March 2020 to a peak of about 851 million USD in September 2021. Following this peak, the net income remains relatively stable around 700 to 1,035 million USD through early 2024, except for a significant negative value recorded in June 2024 (-3.59 billion USD). This sharp negative deviation contrasts markedly with the otherwise consistently positive results. Post this loss, net income reverts to positive figures near historical levels through the latest period in March 2025, though showing some decline relative to prior peaks.
- Revenues
- Revenues exhibit a steady upward trend over the full timeframe. Starting at approximately 1.52 billion USD in early 2020, revenues consistently increase quarter over quarter, reaching a maximum of about 2.91 billion USD in December 2024. Despite minor short-term variations, the general growth pattern is consistent, indicating expanding sales or product uptake during the period analyzed. The March 2025 revenue shows a slight decrease compared to the previous quarter but remains high relative to earlier years.
- Net Profit Margin
- Net profit margin data is concentrated from March 2021 onward and generally maintains a healthy range between 29.8% and 39.46%, evidencing robust profitability relative to revenues. The margin remains stable and high through early 2024, indicating efficient cost and expense management relative to earnings. However, a pronounced decline occurs concurrently with the extraordinary net loss in June 2024, where margins turn negative (approximately -4.74% to -8.91%) for subsequent quarters, reflecting the significant dip in profitability. Margins do not recover to previous levels by March 2025, implying a period of financial strain or one-time adverse impacts affecting profitability.
- Overall Insights
- The financial data reveals a company experiencing general revenue growth and strong profitability from 2020 through early 2024. The presence of considerable net income and stable profit margins during most quarters highlights operational strength. However, the sharp net loss and negative profit margins in mid-2024 mark a significant anomaly that interrupts this trend, suggesting a major expense, write-down, or unusual event impacting financial results. The resumption of positive net income post-loss, albeit with reduced margins, indicates partial recovery but lingering challenges. Continuous revenue growth despite these challenges suggests solid underlying business performance.
Return on Equity (ROE)
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Net income (loss) | ||||||||||||||||||||||||||||
Shareholders’ equity | ||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||
ROE1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
ROE, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
ROE = 100
× (Net income (loss)Q1 2025
+ Net income (loss)Q4 2024
+ Net income (loss)Q3 2024
+ Net income (loss)Q2 2024)
÷ Shareholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis reveals several noteworthy trends and fluctuations in the financial performance over the observed quarters.
- Net Income (Loss)
- Net income showed a generally positive trajectory from 2020 through early 2024, with quarterly values frequently exceeding $600 million and peaking above $1 billion in some quarters of 2023 and early 2024. However, a significant anomaly occurred in the quarter ending June 30, 2024, where net income turned sharply negative (-$3.59 billion), indicating a substantial loss. This loss disrupted the otherwise consistent profitability pattern. After this dip, net income rebounded to positive figures in subsequent quarters, though with some variability.
- Shareholders’ Equity
- Shareholders’ equity demonstrated steady growth throughout most of the periods, increasing from approximately $6.46 billion in early 2020 to a peak of around $18.55 billion by the first quarter of 2024. Following the peak, there was a notable decline in the second quarter of 2024 to about $14.77 billion, coinciding with the large net loss reported. After this drop, shareholders’ equity slightly recovered and stabilized around $16.4 billion by early 2025.
- Return on Equity (ROE)
- The ROE metric, available from the first quarter of 2021 onward, exhibited strong performance, generally ranging between 20% and 31% through early 2024. This indicates efficient use of equity to generate profits during this time. However, consistent with the observed net loss in the second quarter of 2024, ROE turned negative, posting values between approximately -3% and -6% over the remaining quarters, reflecting the adverse profitability situation and reduced returns for shareholders during that interval.
Overall, the data illustrates a firm with stable and robust earnings and equity growth until mid-2024, when an extraordinary loss had a material impact on profitability and equity value. This event temporarily reversed the positive trends in net income and ROE but was followed by a partial recovery. The financial metrics suggest resilience but also underline a period of heightened volatility and risk during the mid-2024 timeframe.
Return on Assets (ROA)
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Net income (loss) | ||||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||||
ROA1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
ROA, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
ROA = 100
× (Net income (loss)Q1 2025
+ Net income (loss)Q4 2024
+ Net income (loss)Q3 2024
+ Net income (loss)Q2 2024)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable trends and fluctuations over the reported periods. Net income exhibits variability with periods of growth and decline, while total assets show a consistent upward trend except for a notable dip towards the later quarters. Return on Assets (ROA) demonstrates marked volatility, particularly a significant decline in recent quarters.
- Net Income
- Net income shows a generally positive pattern with fluctuations over the quarters. From March 31, 2020, net income increased sharply in subsequent quarters, reaching peaks in September 2021 (851,928 thousand USD) and September 2023 (1,035,300 thousand USD). However, there is a pronounced negative impact in June 30, 2024, where net income falls drastically to -3,593,600 thousand USD, indicating a potential one-off loss or extraordinary expense in that period. Following this, net income recovers again but remains somewhat lower than the peaks observed in previous years.
- Total Assets
- Total assets consistently increase from 8,893,201 thousand USD at the beginning of the period to a peak of 23,917,400 thousand USD in March 31, 2024. This growth suggests ongoing asset accumulation or valuation increases, reflecting business expansion or capitalization. After the peak, a sharp decline to 20,132,100 thousand USD follows in June 30, 2024, aligning with the net income loss in the same period, suggesting a possible impairment, asset sale, or revaluation event. Afterwards, assets grow steadily again, reaching 22,880,500 thousand USD by March 31, 2025.
- Return on Assets (ROA)
- ROA data is missing in early quarters but becomes available from December 31, 2020. Initially, ROA is strong, ranging from approximately 16.3% to 23.07%, indicating efficient asset use to generate profits. Over time, ROA gradually declines, reaching lower teens by the end of 2023 and early 2024. A sharp downturn in ROA is evident starting March 31, 2024, turning negative and worsening through the following quarters, with values as low as -4.32%. This sharp decline suggests a period of inefficiency or losses relative to assets, coinciding with the negative net income and reduced total assets in the same period.
In summary, the company demonstrates robust asset growth and profitability until early 2024, when a significant financial disturbance occurs marked by a steep net income loss, asset contraction, and deteriorated asset profitability. Recovery signs appear post this period but with continued lower profitability ratios compared to earlier highs. These patterns suggest that the company may have experienced extraordinary events or financial challenges in mid-2024 impacting overall performance and asset valuation.